Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,320
datasets available to search
ShareScore release 0.9.0
Dataset results
1,320 results for “degeneration”
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00658619. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
ClinicalTrials.gov study NCT01528605. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
ClinicalTrials.gov study NCT01115231. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ClinicalTrials.gov study NCT05230537. IPD Sharing: YES. Countries: 4. Publications: 1.
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT02510794. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Ectopic expression of BBS1 rescues male infertility, but not retinal degeneration, in a BBS1 mouse model
Open the record for dataset details and reuse information.
Data from: Two genes, one culprit - a functional candidate validation of a <em>SPATA7</em> deletion in dogs with day blindness/retinal degeneration
Open the record for dataset details and reuse information.
Alpha and helion particle charge radius difference by spectroscopy of quantum-degenerate helium
Open the record for dataset details and reuse information.
Data from: Quantifying changes on optical coherence tomography in eyes receiving treatment for neovascular age-related macular degeneration
Open the record for dataset details and reuse information.
Data from: One and two year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource
Open the record for dataset details and reuse information.
Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa
Open the record for dataset details and reuse information.
Data from: Rewinding the ratchet: Rare recombination locally rescues neo-W degeneration and generates plateaus of sex-chromosome divergence
Open the record for dataset details and reuse information.
The insidious degeneration of white matter and cognitive decline in Fabry disease
Open the record for dataset details and reuse information.
Data from: A SACS deletion variant in Great Pyrenees dogs causes autosomal recessive neuronal degeneration
Open the record for dataset details and reuse information.
GTPBP2 in-frame deletion in a canine model with progressive retinal degeneration
Open the record for dataset details and reuse information.
Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration
Open the record for dataset details and reuse information.
Data from: A prospective harmonized multicentre DTI study of cerebral white matter degeneration in ALS
<p>Objective: To evaluate progressive white matter (WM) degeneration in ALS.</p> <p>Methods: Sixty-six patients with ALS and 43 healthy controls were enrolled in a prospective, longitudinal, multicentre study in the Canadian ALS Neuroimaging Consortium (CALSNIC). Participants underwent a harmonized neuroimaging protocol across 4 centres including diffusion tensor imaging (DTI) for assessment of WM integrity. Three visits were accompanied by clinical assessments of disability (ALSFRS-R) and upper motor neuron (UMN) function. Voxel-wise whole brain and quantitative tractwise DTI assessments were done at baseline and longitudinally. Correction for site variance incorporated data from healthy controls and from healthy volunteers that underwent the DTI protocol at each centre.</p> <p>Results: ALS patients had a mean progressive decline in fractional anisotropy (FA) of the corticospinal tract (CST) and frontal lobes. Tractwise analysis revealed reduced FA in the CST, corticopontine/corticorubral and corticostriatal tracts. CST FA correlated with UMN function and frontal lobe FA with the ALSFRS-R. A progressive decline in CST FA correlated with a decline in the ALSFRS-R and worsening UMN signs. Patients with fast vs slow progression had a greater reduction in FA of the CST and upper frontal lobe.</p> <p>Conclusions: Progressive WM degeneration in ALS is most prominent in the CST and frontal lobes, and to a lesser degree in the corticopontine/corticorubral tracts and the corticostriatal pathways. With the use of a harmonized imaging protocol and incorporation of analytical methods to address site-related variances, this study is an important milestone towards developing DTI biomarkers for cerebral degeneration in ALS.</p>
Quantitative analysis of optical coherence tomography for neovascular age-related macular degeneration using deep learning
<p><strong>Purpose:</strong> To apply a deep learning algorithm for automated, objective, and comprehensive quantification of optical coherence tomography (OCT) scans to a large real-world dataset of eyes with neovascular age-related macular degeneration (AMD), and make the raw segmentation output data openly available for further research.</p> <p><strong>Design:</strong> Retrospective analysis of OCT images from the Moorfields Eye Hospital AMD Database.</p> <p><strong>Participants:</strong> 2473 first-treated eyes and another 493 second-treated eyes that commenced therapy for neovascular AMD between June 2012 and June 2017.</p> <p><strong>Methods:</strong> A deep learning algorithm was used to segment all baseline OCT scans. Volumes were calculated for segmented features such as neurosensory retina (NSR), drusen, intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM), retinal pigment epithelium (RPE), hyperreflective foci (HRF), fibrovascular pigment epithelium detachment(fvPED), and serous PED (sPED). Analyses included comparisons between first and second eyes, by visual acuity (VA) and by race/ethnicity, and correlations between volumes.</p> <p><strong>Main outcome measures:</strong> Volumes of segmented features (mm3), central subfield thickness (CST).</p> <p><strong>Results:</strong> In first-treated eyes, the majority had both IRF and SRF (54.7%). First-treated eyes had greater volumes for all segmented tissues, with the exception of drusen, which was greater in second-treated eyes. In first-treated eyes, older age was associated with lower volumes for RPE, SRF, NSR and sPED; in second-treated eyes, older age was associated with lower volumes of NSR, RPE, sPED, fvPED and SRF. Eyes from black individuals had higher SRF, RPE and serous PED volumes, compared with other ethnic groups. Greater volumes of the vast majority of features were associated with worse VA.</p> <p><strong>Conclusion:</strong> We report the results of large scale automated quantification of a novel range of baseline features in neovascular AMD. Major differences between first and second-treated eyes, with increasing age, and between ethnicities are highlighted. In the coming years, enhanced, automated OCT segmentation may assist personalization of real-world care, and the detection of novel structure-function correlations. These data will be made publicly available for replication and future investigation by the AMD research community.</p>
Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation
<p><b>Background:</b> To describe 10-year trends in visual outcomes, anatomical outcomes, and treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD).</p> <p><b>Methods: </b>Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤ 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ≥ 70 letters; proportion of eyes with BCVA ≥ 70 and ≤ 35 letters at 10 years; mean trend of BCVA and central retinal thickness (CRT) over 10 years; and mean number of injections.</p> <p><b>Results: </b>For our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching ≤35 and ≥70 letters were 37.8 (95% CI 22.2-65.1) and 8.3 (95% CI 4.8-20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was ≤35 letters and ≥70 letters in 41.1% and 21%, respectively, in first-affected eyes, whilst this was the case for 5.4% and 48.2%, respectively, in a patient's better-seeing eye. Mean injection number was 37.0 ± 24.2 per eye and 53.6 ± 30.1 at patient-level (63.1% of patients required injections in both eyes). </p> <p><b>Conclusions: </b>The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.</p>
Pupil and masking responses to light as functional measures of retinal degeneration in mice Mus Musculus
<p><b>Background: </b>Pre-clinical testing of retinal pathology and treatment efficacy depends on reliable and valid measures of retinal function. The electroretinogram (ERG) and tests of visual acuity are the ideal standard, but can be unmeasurable while useful vision remains. Non-image-forming responses to light such as the pupillary light reflex (PLR) are attractive surrogates. However, it is not clear how accurately such responses reflect changes in visual capability in specific disease models. The purpose of this study was to test whether measures of non-visual responses to light correlate with previously determined visual function in two photoreceptor degenerations.</p> <p><b>Methods: </b>The sensitivity of masking behavior (light induced changes in running wheel activity) and the PLR were measured in 3-month-old wild-type mice (WT) with intact inner retinal circuitry, <i>Pde6b</i>-<i>rd1/rd1 </i>mice (<i>rd1</i>) with early and rapid loss of rods and cones, and <i>Prph2-Rd2/Rd2</i> mice (<i>Rd2</i>) with slowly progressing loss of rods and cones.</p> <p><b>Results: </b>In <i>rd1</i> mice, negative masking had increased sensitivity, positive masking was absent, and the sensitivity of the PLR was severely reduced. In <i>Rd2</i> mice, positive masking identified useful vision at higher light levels, but there was a limited decrease in the irradiance sensitivity of negative masking and the PLR, and the amplitude of change for both underestimated the reduction in irradiance sensitivity of image-forming vision.</p> <p><b>Conclusions: </b>Together these data show that in a given disease, two responses to light can be affected in opposite ways, and that for a given response to light, the change in the response does not accurately represent the degree of pathology. However, the extent of the deficit in the PLR means that even a limited rescue of rod/cone function might be measured by increased PLR amplitude. In addition, positive masking has the potential to measure effective treatment in both models by restoring responses or shifting thresholds to lower irradiances.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.